Black Diamond Therapeutics (NASDAQ:BDTX - Free Report) had its price objective boosted by HC Wainwright from $11.00 to $12.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Black Diamond Therapeutics' Q1 2025 earnings at ($0.32) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.
BDTX has been the subject of a number of other reports. Wedbush reiterated an "outperform" rating and set a $11.00 target price (down from $16.00) on shares of Black Diamond Therapeutics in a research note on Friday, March 7th. Stifel Nicolaus decreased their target price on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Black Diamond Therapeutics presently has a consensus rating of "Buy" and an average target price of $14.60.
View Our Latest Stock Analysis on Black Diamond Therapeutics
Black Diamond Therapeutics Trading Down 5.3 %
BDTX stock traded down $0.10 during midday trading on Tuesday, hitting $1.78. The company's stock had a trading volume of 5,916,558 shares, compared to its average volume of 1,374,063. The company has a market cap of $100.86 million, a PE ratio of -1.34 and a beta of 2.52. Black Diamond Therapeutics has a 12 month low of $1.59 and a 12 month high of $7.66. The firm's 50-day moving average is $2.16 and its 200-day moving average is $2.89.
Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03. Analysts expect that Black Diamond Therapeutics will post -1.3 earnings per share for the current year.
Insider Transactions at Black Diamond Therapeutics
In other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the company's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total value of $11,973,484.44. Following the completion of the sale, the insider now directly owns 2,733,547 shares in the company, valued at $5,658,442.29. This represents a 67.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 8.87% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Black Diamond Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Walleye Capital LLC purchased a new stake in shares of Black Diamond Therapeutics in the 3rd quarter worth $49,000. Intech Investment Management LLC purchased a new stake in shares of Black Diamond Therapeutics in the 3rd quarter worth $56,000. D. E. Shaw & Co. Inc. purchased a new stake in shares of Black Diamond Therapeutics in the 4th quarter worth $37,000. JPMorgan Chase & Co. increased its stake in shares of Black Diamond Therapeutics by 429.6% in the 4th quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company's stock worth $41,000 after purchasing an additional 15,355 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Black Diamond Therapeutics in the 4th quarter worth $42,000. 95.47% of the stock is currently owned by hedge funds and other institutional investors.
Black Diamond Therapeutics Company Profile
(
Get Free Report)
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
See Also
Before you consider Black Diamond Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Black Diamond Therapeutics wasn't on the list.
While Black Diamond Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
